TransMedics Group (TMDX) Misses Q3 EPS by 17c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TransMedics Group (TMDX) PT Lowered to $125 at Oppenheimer
October 29, 2024 6:04 AM EDTOppenheimer analyst Suraj Kalia lowered the price target on TransMedics Group (NASDAQ: TMDX) to $125.00 (from $200.00) while maintaining a Outperform rating.
The analyst comments "TransMedics reported 3Q24 revs. of $108.8M, below our/consensus $117.1M/$115.0M estimates. In Q3, our calculated US transplant shares were 21%/27%/4%... More
